drugset / Trial / NCT02693002

Estrogen Diastolic Heart Failure

NCT02693002

Phase 4 Terminated 4 enrolled Gretchen Wells
RandomizedParallel-groupTriple-blindPrevention

Summary

Peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (BNP).

Timeline

Start
2016-02
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 1 mg Oral
Comparator Norethindrone Unknown 0.5 mg Oral

Indications

No indication recorded.